Zi Yang Shi

Researchers are evaluating the safety and effectiveness of inhaled Peginterferon alpha-2b given at different doses along with supportive care to treat children aged 1 to 6 years with common hand, foot, and mouth disease (HFMD). This clinical trial aims to enroll 90 patients who have developed fever or rash symptoms within 72 hours before joining the study. The trial focuses on patients with ordinary type HFMD and does not include severe or critical cases. Participants will be randomly assigned to one of two groups: one group will receive supportive care plus nebulized Peginterferon alpha-2b at 45 micrograms per dose, and the other group will receive supportive care plus nebulized Peginterferon alpha-2b at 90 micrograms per dose. The medication will be administered on Day 1 and Day 3 during the inpatient visit. Before treatment, there is a 3-day screening period, followed by a 5 to 7 day hospital stay for treatment and monitoring. During the study, researchers will monitor the resolution time for symptoms including fever, skin rash, oral ulcers, and feeding difficulties, focusing on days 5 to 7. Patients will receive symptomatic supportive therapy alongside the investigational drug. Safety and efficacy will be assessed through clinical evaluations and symptom tracking throughout the inpatient period. The study results will help determine the safety and potential benefits of inhaled Peginterferon alpha-2b for HFMD in young children.

Researchers are evaluating the safety and effectiveness of low-dose tenecteplase in elderly patients who have experienced an acute ischemic stroke. This prospective, multicenter, randomized controlled Phase 4 trial focuses on patients aged 70 years and older who receive treatment within 4.5 hours of stroke onset. The study aims to compare low-dose tenecteplase with the standard dose to understand its impact on stroke recovery in aging patients. Participants are randomly assigned to one of two groups: a low-dose group receiving tenecteplase at 0.175 mg/kg (up to 17.5 mg per patient) or a standard-dose group receiving tenecteplase at 0.25 mg/kg (up to 25 mg per patient). Treatment is administered intravenously as thrombolysis. The trial monitors patients closely to assess how these dosing strategies affect recovery and safety. During the study, researchers will evaluate neurological function using the Modified Rankin Scale 90 days after treatment, measuring the percentage of participants who achieve a score of 0 or 1, indicating no symptoms or no significant disability. Patients will undergo neurological assessments and safety monitoring throughout the trial. The study ensures informed consent and collects relevant clinical data to support its findings on tenecteplase use in elderly stroke patients.